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ABSTRACT
Biology-based markers that can be used to confirm the diagnosis of chronic graft-versus-host disease
(GVHD) or monitor progression of the disease could help in the evaluation of new therapies. Biomarkers
have been defined as any characteristic that is objectively measured and evaluated as an indicator of a
normal biologic or pathogenic process, a pharmacologic response to a therapeutic intervention, or a
surrogate end point intended to substitute for a clinical end point. The following applications of biomar-
kers could be useful in chronic GVHD clinical trials or management: (1) predicting response to therapy;
(2) measuring disease activity and distinguishing irreversible damage from continued disease activity; (3)
predicting the risk of developing chronic GVHD; (4) diagnosing chronic GVHD: (5) predicting the
prognosis of chronic GVHD; (6) evaluating the balance between GVHD and graft-versus-leukemia effects
(graft-versus-leukemia or GVT); and (7) serving as a surrogate end point for therapeutic response. Such
biomarkers can be identified by either hypothesis-driven testing or by high-throughput discovery-based
methods. To date, no validated biomarkers have been established for chronic GVHD, although several
candidate biomarkers have been identified from limited hypothesis-driven studies. Both approaches have
his project was supported by the National Institutes of Health (NIH) National Cancer Institute, Ofﬁce of the Director, Cancer Therapy Evaluation
rogram, Intramural Research Program and Center for Cancer Research; National Heart Lung and Blood Institute, Division of Blood Diseases and
esources; Ofﬁce of Rare Diseases, NIH, Ofﬁce of the Director; National Institute of Allergy and Infectious Disease, Transplantation Immunology Branch;
nd the Health Resources and Services Administration, Division of Transplantation and the Naval Medical Research Center, C. W. Bill Young/Department
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Biomarkers in Chronic GVHD
Bmerit and should be pursued. The consistent treatment and standardized documentation needed to
support biomarker studies are most likely to be satisfied in prospective clinical trials.
© 2006 American Society for Blood and Marrow Transplantation
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6ACKGROUND
The approach currently used to establish the di-
gnosis of chronic graft-versus-host disease (GVHD)
epends almost exclusively on the clinical history,
hysical examination, and histopathologic conﬁrma-
ion. This approach is not fully informative in predict-
ng the severity of the disease, response to therapy, or
urvival, and is not adequate to distinguish disease
ctivity from irreversible tissue damage during treat-
ent. These limitations may be best illustrated by the
ifﬁculty of designing appropriate inclusion criteria
or clinical trials to treat chronic GVHD. Improve-
ents could come from biologically based indicators
r markers that could be used together with or in place
f standard clinical and histologic criteria for diagnos-
ng chronic GVHD, or for predicting or evaluating
he response to therapy.
URPOSE OF THIS DOCUMENT
The purpose of this document is to identify an
pproach for the identiﬁcation, validation, and appli-
ation of biomarkers for chronic GVHD. Toward this
oal, this document provides: (1) deﬁnitions of bi-
markers and their applications; (2) a proposed clas-
iﬁcation of biomarkers by pathophysiological pro-
ess-speciﬁc pathways in chronic GVHD; (3)
ethodologic considerations in the identiﬁcation and
easurement of biomarkers for chronic GVHD; (4)
urrent applications of biomarkers in chronic GVHD,
nd (5) recommendations for validation studies.
UMMARY OF RECOMMENDATIONS
The Biomarkers Working Group made the fol-
owing recommendations.
. A multidisciplinary, coordinated approach to the identi-
ﬁcation, validation, and application of biomarkers should be
supported, particularly within the context of clinical ther-
apeutic trials.
. Both hypothesis-driven and discovery-based approaches
for identiﬁcation of chronic GVHD biomarkers should
be pursued simultaneously.
. Chronic GVHD clinical therapeutic trials should in-
clude correlative biologic studies focused on the identiﬁ-
cation, validation, and application of biomarkers when-
ever possible. t
B&MT. Samples from well-documented cases with and without
chronic GVHD should be stored to create a resource for
future biomarker studies.
. Once chronic GVHD biomarkers have been validated,
selected biomarkers should be tested for use as surrogate
end points in clinical trials.
EFINITIONS OF BIOMARKERS AND THEIR
PPLICATIONS
Biomarkers have been deﬁned as characteristics
hat are objectively measured and evaluated as indica-
ors of normal biologic or pathogenic processes, phar-
acologic responses to a therapeutic intervention, or
s a surrogate end point intended to substitute for a
linical end point. As a secondary goal, biomarkers
ould be used to elucidate the biologic mechanisms of
disease. For the purposes of this document, certain
valuations that are routinely performed to determine
he diagnosis of chronic GVHD or to assess the se-
erity of the disease were not considered as biomark-
rs. Examples of such evaluations include skin, liver,
nd intestinal biopsies, pulmonary functions tests,
igh-resolution computed tomography scans, perfor-
ance scores, and Schirmer’s tests.
Biomarkers could be used for a variety of purposes.
. Predict response to therapy. For example, a biomar-
ker could be developed to guide the choice of treatment.
. Measure disease activity and distinguish irrevers-
ible damage from continued disease activity. For
example, a biomarker could identify changes that may
improve with therapy, as distinguished from those that
will not.
. Predict risk of developing chronic GVHD. For
example, gene polymorphisms in either the donor or
recipient may be associated with risk of chronic GVHD.
. Diagnose chronic GVHD. For example, a biomarker
could be used together with clinical criteria to determine
eligibility for a clinical trial.
. Assess prognosis or establish staging of chronic
GVHD. For example, a biomarker could be used to
determine the risk category or to guide decisions about
the need for treatment.
. Evaluate GVHD versus graft-versus-leukemia (GVL)
or graft-versus-tumor (GVT) effect. Biomarkers
could also be used to assess the GVL or GVT response in
patients who have hematopoietic cell transplantation to
treat malignancy.
Biomarkers that could be used to predict responseo treatment, measure disease activity, or distinguish
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1eversible disease activity from irreversible damage
ould have very high clinical use, because currently
vailable clinical tools are not adequate for these pur-
oses. On the other hand, biomarkers that could pre-
ict risk of developing chronic GVHD would likely
ave lower use, because interventions that could be
sed to change the risk of chronic GVHD are not
urrently available. Biomarkers that could be used to
iagnose chronic GVHD would have lower use, be-
ause very good clinical tools have already been estab-
ished for this purpose. Similarly, biomarkers that
ould assess the prognosis of chronic GVHD would
ave limited use, because clinical indicators of nonre-
apse mortality have already been established. Lastly,
iomarkers that could weigh GVHD versus GVL ef-
ects (GVL or GVT) would have limited use, because
he relative clinical threats of chronic GVHD and
ecurrent malignancy can be reasonably well assessed
hrough the use of currently available clinical indica-
ors.
Clinical end points are of greatest relevance in
stablishing relevant measures of a therapeutic re-
ponse. These end points assess how a patient feels,
unctions, or survives. A surrogate end point is ex-
ected to predict clinical beneﬁt (or harm or lack of
eneﬁt) based on epidemiologic, therapeutic, patho-
hysiologic, or other scientiﬁc evidence [1]. Biomar-
ers can be used as surrogate end points in clinical
rials only after extensive validation. After such vali-
ation, surrogate end points can be used to indicate
herapeutic response before a clinical response has
ccurred and could be very useful for regulatory re-
iew [2].
ROPOSED CLASSIFICATION OF BIOMARKERS BY
ATHOLOGIC PROCESS-SPECIFIC PATHWAYS IN
HRONIC GVHD
Numerous studies have been carried out to eval-
ate biomarkers for correlation with the presence or
bsence of chronic GVHD. These biomarkers can be
ategorized according to processes or mechanisms by
hich they are thought to contribute to the pathogen-
sis of chronic GVHD (Table 1), and in many cases,
hey correlate either qualitatively or quantitatively in
ne way or another with chronic GVHD activity.
llogeneic Disparity
HLA antigen mismatching is associated with an
ncreased risk of chronic GVHD [3]. Other biomark-
rs for allogeneic disparity include nonsynonymous
ingle nucleotide polymorphisms in genes encoding
inor histocompatibility antigens that differ between
he donor and recipient. This hypothesis is supported
y observations that the risk of chronic GVHD is
ncreased when the donor and recipient have different f
28acial or ethnic origins [4]. It is also possible that
ndividual HLA antigen molecules reduce (or in-
rease) the risk of chronic GVHD by preferentially
resenting a selected repertoire of minor histocom-
atibility antigens [5]. Lastly, the association of
hronic GVHD with increased numbers of activated B
ells and anti-HLA antigen antibodies highlight the
ole of allogeneic disparity in the pathogenesis of
hronic GVHD [6].
irect Allogeneic Immune Responses Against
pecific Antigens
Evaluations of direct allogeneic immune responses
ave not demonstrated strong correlation between the
umber of minor histocompatibility antigen-speciﬁc
cells and the presence of chronic GVHD [7,8]. In
eneral, the antigens recognized by these donor-de-
ived recipient-reactive T-cell populations are poorly
haracterized, and the response of donor T cells
gainst recipient alloantigens appears to be highly
eterogeneous and polyclonal. The best characterized
inor histocompatibility antigens presented by major
istocompatibility complex class I molecules are en-
oded on the Y chromosome. These H-Y antigens
ave been invoked to explain why the incidence of
hronic GVHD is higher with the use of female do-
ors for male recipients than with other donor and
ecipient sex combinations. Higher frequencies of T
ells recognizing H-Y antigens presented by HLA-A2
nd HLA-B7 molecules correlate with the presence of
hronic GVHD, and the number of H-Y reactive T
ells decreases after response to GVHD therapy [9].
A-1 is another antigen that may be recognized in the
evelopment of chronic GVHD. Results of one study
howed that HA-1–reactive T cells are present in
atients with GVHD and that their frequencies de-
rease as GVHD improves during therapy [9]. Subse-
uent studies have shown a correlation of HA-1 mis-
atch with risk of acute GVHD but not with chronic
VHD [10]. The low frequency of HA-1 disparity
akes it difﬁcult to test associations with clinical out-
ome [11]. Results of another study showed that re-
ipient mismatching for CD31 at all 3 codons 125,
63, and 670 was associated with an increased risk of
cute GVHD and with a trend suggesting an increased
isk of chronic GVHD [12]. Results of these studies
eed to be conﬁrmed.
A B-cell response to H-Y minor histocompatibil-
ty antigens correlates with the development of
hronic GVHD. Increased titers of antibodies reactive
ith donor and H-Y antigen have been shown to be
resent in patients with chronic GVHD [13,14]. Al-
hough the anti-H-Y antibody response might be
romising as a marker of chronic GVHD, this re-
ponse can occur only in male patients who have
emale donors.
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BSome groups have also evaluated T-cell clonality
s a marker for chronic GVHD. Clonal T cells have
een isolated from patients with myositis resulting
rom chronic GVHD [15]. Others have shown that
linical improvement during photopheresis occurred
ore frequently among patients with clonal T-cell
eceptor- rearrangements than among those who did
ot have such rearrangements [16]. The interpreta-
ion of these studies remains uncertain, because
any patients without chronic GVHD have clonal
xpansions of T cells as part of the typical pattern of
mmune reconstitution after hematopoietic cell trans-
lantation [17].
nflammatory Responses
Chronic GVHD has been associated with allo-
able 1. Proposed Classiﬁcation of Biomarkers Based on Process-Speciﬁc
Type of Response Examples
llogeneic disparity [3-8] HLA-A, B, DR
irect allogeneic immune
response
measurements [7-17]
Immunity against minor
histocompatibility antigens
(MiHA) (e.g. H-Y, HA-1)
nonspecific autoantibodies
(ASMA, ANA)
nflammatory responses
[18-36]
Th1/Tc1 and Th2/Tc2
DC1 and DC2
Eosinophils
CpG response (TLR9)
NOD2 polymorphism (TLR2)
egulatory immune cell
populations [37-54]
Regulatory T cells (Treg)
Antigen-presenting cells (B cells
mmune-modulatory
consequences of
chronic GVHD or
therapy [31,55-59]
TREC and TCR V repertoire
analyses, and chimerism
(T and B cells, DCs), Platelet
counts, salivary IgA
onimmune chronic
GVHD biomarkers [28]
Von Willebrand factor and
thrombomodulin
LA indicates human leukocyte antigens; GVHD, graft-versus-hos
ELISA, enzyme-linked immunosorbent assay; MiHA, minor hist
reverse transcriptase polymerase chain reaction; CpG ODN, Cp
cells.eactive helper and cytotoxic T cells, nonspeciﬁc sup- h
B&MTressor cells, tumor necrosis factor-–secreting mac-
ophages, and autoreactive T cells [18,19]. In human
eings, chronic GVHD may involve an alteration in
he balance of helper T cell type 1/cytotoxic T cell
ype 1 (Th1/Tc1) and helper T cell type 2/cytotoxic T
ell type 2 (Th2/Tc2) populations, with a predomi-
ant Th1/Tc1 response characterized by an aberrant
attern of interferon (IFN)- production without in-
erleukin (IL)-2 production. Chronic GVHD has
een associated with increased proportions of CD8
ells lacking CD28 [20] and a decreased proportion of
atural killer (CD3/CD16/CD56) cells in the
lood [20]. Cytokines also play a role in certain disease
anifestations. Sclerosis has been associated with high
oncentrations of transforming growth factor-,
hereas fatigue and wasting have been associated with
nisms in Chronic Graft-versus-Host Disease
Methods of Measurement Comments
HLA typing, incompatibility
SNPs
HLA typing well established
as a prognostic marker
for development of
chronic GVHD
MiHA-reactive antibodies
(ELISA)
MiHA reactive T cells and
B cells (ELISPOT,
proliferation assays,
tetramer)
Only indirect evidence for
H-Y antigen involvement
No established correlation
between chronic GVHD
and any other HA
Immunophenotyping,
Stimulation assays with
measurement of cytokine
production, SNP for
cytokine polymorphisms
Stimulation assays, SNP,
RT-PCR
Chronic GVHD may involve
Th1- and Th2-driven
pathology.
Cytokine polymorphism
may be predictive of
development of chronic
GVHD
Early unpublished
correlation of CpG ODN
response and
NOD2/CARD15
polymorphism.
Immunophenotyping, PCR
for Foxp3, functional
studies evaluating
regulatory T cells
The role of Treg cells at
present is controversial,
as different studies have
shown opposing results
The response of chronic
GVHD to rituximab
therapy suggests a role
for B cells outside
antibody production.
Immunophenotyping
chimerism studies
Single center studies at
present
Standard laboratory Only single center
observation
e; TREC, T cell restriction excision circles; TCR, T cell receptor;
atibility antigens; ELISpot, enzyme-linked immunospot; RT-PCR,
odeoxynucleotide; Treg, regulatory T cells; DC1, type 1 dendriticMecha
)
t diseas
ocomp
G oligigh concentrations tumor necrosis factor-, and im-
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1unodeﬁciency has been associated with high concen-
rations of IL-10 and transforming growth factor-
21].
Reduced expression of IL-10 and increased IFN-
roduction has been described in patients with chronic
VHD as compared with healthy individuals and pa-
ients without GVHD, suggesting a more prominent
ole for Th1 cytokines in human chronic GVHD than in
urine chronic GVHD [22]. These ﬁndings are further
upported by the increased expression of IFN- de-
ected in skin biopsy specimens from patients with
utaneous chronic GVHD [23]. Transcription of the
h2 cytokines IL-4 and IL-5 was not detected in these
kin samples, and IL-10 expression was not signiﬁ-
antly altered as compared with control subjects. In a
eparate study, however, Con A-stimulated T-cell
roduction of IFN- was decreased in patients with
hronic GVHD [24]. The consistent presence of au-
oantibodies against cytoskeletal proteins (tubulin, ac-
in, myosin) indirectly supports a role for donor Th2
ells in human chronic GVHD [25]. Overall, it ap-
ears that chronic GVHD can present with either
h1/Tc1 or Th2/Tc2 predominance, and it is likely
hat predominance of one or the other may produce
ifferent clinical manifestations.
CD4 T cells can be divided into 3 classes: (1)
aive (CD45RA/CCR7/CD62Lhi); (2) central mem-
ry (CD45RA/CCR7/CD62Lhi); and (3) effector
emory (CD45RA/CCR7/CD62Llow). Whereas
entral memory CD4 T cells can have either Th1 or
h2 proﬁles, effector memory CD4 T cells produce
igh levels of IFN-, IL-4, and IL-5, and they pro-
uce moderate levels of IL-2 [26]. Severe chronic
VHD is associated with a preponderance of CD4
ffector memory cells as opposed to central memory
ells [27].
CD8 T cells appear to be important effectors in
hronic GVHD. CD8 T cells inﬁltrates correlate
ith microvessel loss in the skin [28], and increased
ytolytic CD8 T cells are found in intestinal biopsy
pecimens from patients with chronic GVHD [29].
linical improvement during extracorporeal photo-
heresis has been associated with decreased numbers
f CD8 T cells and increased numbers of CD4 T
ells in patients with chronic GVHD, but the changes
ere not striking [30]. The onset of chronic GVHD
as been associated with T-cell activation, as evi-
enced by OX40 expression on CD4 and CD8 T
ells, and clinical response to therapy has been asso-
iated with decreased T-cell expression of OX40 [31].
Polymorphisms of donor and recipient IL-1 and
L-6 genes have been associated with the incidence
nd severity of chronic GVHD [32]. The donor IL-
-174GG-homozygous genotype causes increased
L-6 production and has been associated with in-
reased incidence and severity of chronic GVHD.
he donor tumor necrosis factor receptor type II p
3069RR-homozygous genotype has been associated
ith an increased risk of chronic GVHD [33]. An
ncreased risk of chronic GVHD has also been asso-
iated with the recipient IL-10 GG-homozygous ge-
otype and with the recipient IL-1Ra polymorphism,
L1RN*2 [34,35].
egulatory Immune Populations in Chronic
VHD
Both high and low levels of regulatory T-cell pop-
lations have been correlated with the presence of
hronic GVHD [36-41]. Conﬂicting results might be
esolved through studies of Foxp3 expression, a tran-
cription factor that governs the development and
unction of regulatory T cells.
The role of plasmacytoid (IFN-–producing) den-
ritic cells (DCs) in chronic GVHD remains unclear.
ncreased numbers of donor- or host-derived plasma-
ytoid DCs in the blood have been associated with the
resence of chronic GVHD in human beings [4,42].
ther studies, however, have shown that grafts con-
aining higher numbers of plasmacytoid DCs were
ssociated with a lower incidence of chronic GVHD
nd a higher risk of recurrent leukemia [43]. The
ncreased incidence of chronic GVHD observed after
ranulocyte colony-stimulating factor–stimulated blood
ell transplantation could be caused by a paucity of
lasmacytoid DCs [44].
B cells may facilitate the development of chronic
VHD through their ability to present alloantigens
nd produce autoantibodies. The appearance of TLR9-
ositive activated B cells has been associated with the
evelopment of chronic GVHD [45] and with increased
oncentrations of IgG in the blood [46,47]. Contrasting
ata have shown that decreased B-cell lymphopoiesis
nd decreased numbers of B-cell precursors in the
lood of patients correlate with established chronic
VHD [48] and with a decrease in the numbers of
gA producing plasma cells in the marrow [49]. Anti-
D20 monoclonal antibody has also been reported to
e effective for treatment of chronic GVHD [50,51].
hronic GVHD in human beings is associated with
utoantibody-mediated diseases such as myasthenia
ravis, but the mechanisms that account for autoanti-
ody production remain obscure. Autoantibodies as-
ociated with chronic GVHD can have a variety of
peciﬁcities, including antinuclear antibody, rheuma-
oid factor, antimitochondrial antibody, Coombs an-
ibody, antismooth muscle antibody, anticardiolipin
ntibody, platelet antibodies, and antineutrophil anti-
odies [46,47,52,53].
mmune-Modulatory Consequences of Chronic
VHD
T cells from patients with chronic GVHD are
oorly responsive to mitogen and alloantigen stimu-
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Bation, suggesting the presence of defects in T-cell
ctivation pathways [54,55]. Some investigators have
uggested that the effector cells stimulated by recipi-
nt alloantigens can be identiﬁed by their constitutive
xpression of “activation” markers, including CD69,
L-2R, Fas receptor (CD95), and Fas ligand [31,55-
7]. Autoimmune mechanisms are thought to account
or at least some of the clinical manifestations of
hronic GVHD. Autoimmunity could reﬂect impaired
eletion of autoreactive T cells in the thymus and
ltered presentation of cryptic antigens caused by in-
reased production of IL-6 [58].
onimmune Chronic GVHD Biomarkers
Localized nonimmune biomarkers of chronic
VHD such as Von Willebrand factor and thrombo-
odulin have also been identiﬁed as correlating with
ndothelial damage [28].
ETHODOLOGIC CONSIDERATIONS IN THE
DENTIFICATION AND MEASUREMENT OF
IOMARKERS FOR CHRONIC GVHD
Prospective collection of samples for evaluation of
ither an existing set of hypothesis or discovery-based
tudies or as a resource for future studies is strongly
ncouraged. In the following section, we discuss the
ypes of tissues that may be collected, potential con-
ounding factors, and recommendations around sam-
le acquisition.
issue Location of Markers
Although blood-based biomarkers have received
he most attention, tissue-based biomarkers should
ot be overlooked. For example, cytokine expression
n skin biopsy specimens [24] and increased numbers
f eosinophils in gut biopsy specimens [59] have been
ssociated with chronic GVHD. Tissue eosinophilia
as been associated with increased severity of chronic
VHD and with eosinophilia in the blood [60]. Mast
ells may help to direct T-cell trafﬁcking and activa-
ion in the microvasculature of patients with chronic
VHD [61].
GVHD causes inﬂammation of salivary gland
ucts and increased epithelial permeability in salivary
lands. These changes increase the concentrations of
lbumin, IgG, lactoferrin, and electrolytes in saliva
amples from patients with chronic GVHD [62-65].
ne study found 74% sensitivity and a 91% predictive
alue for associations between salivary Na concentra-
ions and histopathologic ﬁndings of chronic GVHD
n salivary glands [62]. Such salivary changes are also
eversible with decreased inﬂammation [64], suggest-
ng that these measures could be useful in monitoring
he response to therapy. Oral manifestations of
hronic GVHD have been correlated with the pres- a
B&MTnce of GVHD manifestations affecting the eye, liver,
nd skin, suggesting that saliva-based tests could be
sed as a general marker of disease activity [65].
otential Confounding Factors
A variety of confounding factors limit the ability to
nterpret results of many previous biomarker studies.
hese include the onset time of GVHD after trans-
lantation, the age of the recipient, the type of graft
peripheral blood, bone marrow, or umbilical cord
lood), treatment of the donor with granulocyte col-
ny-stimulating factor, the type and intensity of im-
une suppressive treatment (steroids, calcineurin in-
ibitor, mammalian target of rapamycin (mTOR)
nhibitor), the presence of infections, and lingering
ffects of acute GVHD. The interpretation of im-
une-related biomarkers must also account for time
rom transplantation, because immune reconstitution
ccurs gradually, even in the absence of chronic
VHD.
ecommendations for Sample Acquisition
Samples should be banked for future studies with
link to patient data regarding diagnosis of chronic
VHD, GVHD histology, and response to GVHD
herapy as outlined in other working group reports in
manner that complies with regulations for disclosure
f protected health information. We recommend that
onor and patient samples be obtained before trans-
lantation. Additional patient samples should be ob-
ained at the onset of chronic GVHD and whenever
he patient is assessed for response after initiation of
reatment. Because the immune environment changes
ith posttransplantation immune reconstitution,
ime-matched samples should also be obtained from
atients who do not have GVHD. In the absence of
hronic GVHD, samples should be obtained at 3, 6, 9,
2, and 24 months after transplantation. Ideally,
NA, RNA, cells, plasma, and serum from blood and
ther sources such as urine, saliva, bronchoalveolar
avage ﬂuid, and material from tissue biopsy speci-
ens (e.g., skin, oral mucosa, liver, lung) would be
ollected. More realistically, minimum requirements
ould focus on collection of samples at 3, 6, and 12
onths and liquid nitrogen storage of viable periph-
ral blood cells and serum or plasma collected from
he same sample.
Handling of specimens for centralized testing and
ifferences in local processing procedures can con-
ound the assessment of biomarkers, because many
iologic assays may be affected by processing, trans-
ort and storage conditions, and time delay. Standard
rocedures for the collection, processing, storage, and
ransport of samples should be agreed upon widely
mong chronic GVHD centers. Studies to document
ssay sensitivity to these variables should be per-
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1ormed before centralized testing begins. Finally, per-
ission to use samples in future studies and to ex-
hange materials with other institutions should be
mbedded in approved consent documents, thereby
llowing such studies to be conducted in the future
ithout the need for explicit re-consenting of patients.
URRENT APPLICATIONS OF BIOMARKERS IN
HRONIC GVHD
A limited number of biomarkers have been evalu-
ted in hypothesis-driven testing for speciﬁc clinical
pplications (Table 2). The data have come primarily
rom a single center or from a small number of cen-
ers, and in most cases, the ﬁndings have not been
ested as part of large multicenter trials.
. Predict response to therapy. Although some biomarkers
have shown correlations with response during treatment
of chronic GVHD [66] no marker has been identiﬁed as
a predictor of response.
. Measure disease activity and distinguish irrevers-
ible damage from continued disease activity. As
discussed above, a variety of markers correlate in one
way or another with disease activity, but they have not
been used to distinguish irreversible damage from re-
versible disease activity. Speciﬁc tissue markers may be of
particular value for this application.
. Predict risk for developing chronic GVHD. Pre-
liminary results suggest that polymorphisms of the
IL-10 promoter and NOD2/CARD15 [67] could have
use for predicting risk of chronic GVHD.
. Diagnose chronic GVHD. Several markers have the
potential to assist in the diagnosis of chronic GVHD, but
the sensitivity and speciﬁcity of these biomarkers in the
diagnosis of chronic GVHD has received only limited
attention. These include: (a) platelet, absolute lymphocyte,
and eosinophil counts; (b) serum bilirubin, creatinine ki-
nase, and aldolase (myositis) concentrations; (c) serum
immunoglobulin and salivary IgA concentrations; (d) au-
toantibodies including antinuclear, anticardiolipin, antimi-
tochondrial, antismooth muscle, and anti-acetylcholine re-
ceptor. Other markers that still require conﬁrmation in
larger studies include: (a) assessment of H-Y reactive an-
tibodies and B cells; (b) B-cell response to CpG ODN; and
(c) the presence or absence of regulatory cells.
. Assess prognosis of chronic GVHD. The only estab-
lished biomarker for prognosis of chronic GVHD is
platelet count.
. Evaluate GVHD versus GVL effect (GVL or GVT).
Currently the only marker consistently associated with
an increased risk of recurrent malignancy is the persis-
tence of recipient immune cell populations (T cell, B cell,
and DC) after the transplantation.
. Act as surrogate end points for therapeutic response.
No biomarkers have received sufﬁcient study and valida-
tion to justify their use as surrogate end points.
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Biomarkers in Chronic GVHD
BBiomarkers can be identiﬁed both through hy-
othesis-driven and discovery-based methods. To
ate, virtually all studies of chronic GVHD have used
hypothesis-driven approach with a small number of
andidate biomarkers. Discovery-based methods with
he use of high-throughput methods have not yet been
sed to identify biomarkers for chronic GVHD.
igh-throughput methods using microarray-based or
roteinomic-based assays could be used to discover
ew DNA, RNA, or protein biomarkers for chronic
VHD. Such studies could use both structured and
nstructured statistical evaluations for correlation
ith the intended clinical application. The choice
mong DNA, RNA, or protein biomarkers depends
n the speciﬁc application under development. For
xample, DNA-based assays should be perfectly ade-
uate for correlations with risk of GVHD, but they
ould not be useful as measures of disease activity.
he use of RNA-based assays depends on the avail-
bility of specimens that contain cells expressing the
iomarker of interest. For instance, RNA from blood
ells could provide informative immunologic biomar-
ers, to the extent that blood cells participate in the
athogenesis of chronic GVHD. Similar consider-
tions apply for protein-based assays.
ECOMMENDATIONS FOR VALIDATION STUDIES
Most of the listed biomarkers are derived from
ingle center or single laboratory evaluation and have
ot been validated. Validation of chronic GVHD
arkers requires comparison of the biomarker with an
ccepted gold standard for a speciﬁc application. Sev-
ral reasons account for the lack of validation of re-
ults from previous studies. Testing may require rel-
tively difﬁcult laboratory-speciﬁc techniques or
eﬂect the speciﬁc interests of investigators. Tech-
iques for testing may differ among centers, because
here is no forum for development of standardized
iomarkers assays. For example, the lack of standard-
zed assays has made it very difﬁcult to interpret the
esults of assays that measure T-regulatory cells. The
ecent experience of the National Institutes of
ealth–funded Immune Tolerance Network exempli-
es a successful approach toward standardization of
ssays in collaborative biomarker studies.
Validation studies require correlations between
iomarker assessment and standardized clinical data
ocumenting chronic GVHD diagnosis and response
o treatment. Four types of studies will be needed to
evelop biomarkers in chronic GVHD. The initial
iscovery step involves immune reconstitution, pro-
eomics, and microarray studies to generate hypothe-
es. These initial studies are followed by more limited
alidation studies designed to test speciﬁc candidates
rom the discovery results with material from a limited c
B&MTumber of centers. Technical validation is then needed
o demonstrate that testing of validated markers can be
arried out reliably in a larger number of centers and to
onﬁrm the earlier results. The ﬁnal step involves
linical application and validation in large clinical
tudies. At this step the biomarker could be used to
dentify subtypes of chronic GVHD for classiﬁcation
urposes, prognostication, and response to therapy.
It is likely that only large, well-conducted clinical
rials will provide the consistency of treatment and
tandardized documentation needed to support vali-
ation studies correlating biomarkers with response to
herapy. Single or limited institution observational
tudies in which standardized diagnostic criteria are
sed and in which samples are obtained from patients
ith and without chronic GVHDmay be sufﬁcient for
nitial studies correlating biomarkers with the diagno-
is of chronic GVHD. Subsequent validation would
equire the application of similar diagnostic criteria
nd testing of the marker in patient populations across
everal centers. In the absence of a clinical trial, the
nly gold standard for the diagnosis and response to
herapy of chronic GVHD suitable for validation of
hronic GVHD biomarkers is a retrospective evalua-
ion of clinical and histologic data for each case, per-
aps performed by an expert review group.
Although the ideal biomarker will have both high
peciﬁcity and high sensitivity with low false-positive
nd low false-negative rates, some biomarkers may be
elected for either high sensitivity or high speciﬁcity.
s an example in diagnosis, high speciﬁcity may be
ore important than high sensitivity, whereas high
ensitivity may be more important as a response bi-
marker once the diagnosis of chronic GVHD has
een established. Multivariate analyses should be con-
idered to identify potential combinations of biomar-
ers and clinical characteristics that may increase
peciﬁcity. Expert statistical design and analysis is es-
ential for this type of study. Suggested statistical
riteria are included in Appendix 1.
In conclusion, much work will be required both to
alidate candidate biomarkers from previous studies
nd to implement high-throughput methods with ap-
ropriately collected specimens for future discovery-
ases approaches. Close coordination between multi-
pecialty clinical and laboratory-based groups will be
eeded to pursue such studies. Identiﬁcation and val-
dation of biomarkers will greatly assist in the evalu-
tion of new approaches for treatment of chronic
VHD.
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PPENDIX 1: STATISTICAL CONSIDERATIONS FOR
ALIDATION OF BIOMARKERS FOR CHRONIC GVHD
In validating a biomarker, we specify the conditions
f measurement. These include the time of day the
ample is taken (unless known to be unimportant), the
bserver/person doing the measurement, conditions
nown to affect the measurement, type of automated
nstrument, and characteristics of the subject being
easured.
Reliability refers to:
measurements are measuring what we think they
are measuring (face validity).
the measurement is repeatable over time (when
time is short enough that we do not expect a
change in the measurement).
the measurement is repeatable over evaluations
(whether an instrument or a person—and the a
34technique of collection, storage, transport may be
important).
variability of the measurement is small enough for
useful inference to be made.
The variation in a measurement consists of varia-
ion caused by the subject (Vs), variation caused by
nstrument, evaluator, age, sex, etc. We denote the
um of the measurement errors as Ve. We deﬁne
eliability as:
Vs
VsVe
.
his is related to the intraclass correlation coefﬁcient
ICC). We estimate these quantities from the ex-
ected values of the sums of squares from an analysis
f variance table. Other quantities that are used in
eliability evaluation are the coefﬁcient of variation
ratio of the SD to the mean expressed as a percent).
ypically, we want reliability to be “high”–0.8 is ex-
ellent, 0.6 to 0.8 is substantial, 0.4 to 0.6 is moderate,
.2 to 0.4 is fair. Our recommendations are that bi-
markers for chronic GVHD should be selected with
n ICC of greater than 0.6.
We determine face validity by noting how well the
easure agrees with an attribute as determined by
xperienced individuals. In many situations, the at-
ribute determined by experienced individuals is cat-
gorical. In this case, we measure the validity by the
greement between the categories predicted by the
easurement and those determined by consensus.
his could be a 2 statistic or a measure of association
gamma, Spearman, or Kendall correlation).
Content validity is deﬁned as how the biomarker
easures a variety of aspects of the disease. Because
any biomarkers are quite speciﬁc in their measure-
ent aim, this concept may be less useful for biomar-
ers. However, if one is attempting to obtain a global
easure of disease activity or improvement, we can
se a combination of biomarkers and then this concept
ill be helpful.
Construct validity measures the association of one
iomarker with other measures most likely based on
linical and histologic criteria. We measure this by
nonparametric correlation coefﬁcient. Criterion
alidity measures the agreement with a gold stan-
ard.
We expect a biomarker to address a biologic pro-
ess. To address face validity the physician or physi-
ians provide an attribute that the biomarker will
ddress. In some cases, this may be difﬁcult or deter-
ined by the biomarker itself. These may be (ordered)
ategorical or continuous attributes. The biomarker
eed not be in the same scale as the attribute. That is,
he biomarker may be continuous, whereas the at-
ribute may be categorical. The agreement can be
ssessed by various statistical techniques. For example,
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Biomarkers in Chronic GVHD
Bf both attribute and biomarker are continuous, re-
ression (possibly multiple to adjust for age, sex, etc.)
ay be used. If the attribute is an ordered categorical
ariable and the biomarker is continuous, we often use
n ordered logistic regression.
To address the reliability of a measure, the ICC is
idely used. In this case, we conduct an analysis of
ariance and estimate sources of variation from sub-
ect, instrument, evaluator, time, etc. Then, we com-
ute the ICC. Note that one can compute a number of
CCs depending on whether we are concerned with
ubject, instrument, evaluator, or time.
As these studies progress, there will be need to
evelop prognostic indicators, diagnostic indicators,
tc. These will often combine biomarkers and other
ariables to predict outcomes, diagnoses, etc. Thus, it
ill be important to determine the key set of biomar-
ers and to have the full set of key biomarkers for
atients and control subjects. Many statistical methods
re available to combine variables (including biomar-
ers) for these purposes. Multiple linear regression is
seful to predict continuous outcomes; logistic regres-
ion is the widely accepted method for predicting
ichotomous outcomes. However, these methods rely
n linear relationships between predictor and re-
ponse. In some cases, there will be nonlinear re-
ponses. A common one is a threshold response: there
s no response until a variable reaches a certain level.
odels such as classiﬁcation and regression trees have
een very useful in this context. These are exploratory
nalyses that are tailored to the speciﬁc problem ad-
ressed.
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